UroToday

ProsTIC26: Lu-PSMA: Prior or After Surgery? Is there a Role?

The 2026 ProsTIC annual meeting featured a Lutetium-177 session and a presentation by Dr. Renu Eapen discussing whether there ...
ascopubs.org

Cardiometabolic health’s influence on outcomes in men with localized high-risk prostate cancer (HRPCa) treated with pre-operative ADT ± AR pathway inhibition (ARPI).

Examination of Decipher prostate genomic classifier in patients with de novo metastatic disease from a large scale real-world clinical and transcriptomic data linkage. This is an ASCO Meeting Abstract ...
Medical Xpress

Perioperative apalutamide in high-risk localized or locally advanced prostate cancer reduces risk of metastasis, death

High-risk localized and locally advanced prostate cancer patients treated with apalutamide—a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI)—plus hormone therapy before and ...
UroToday

ProsTIC26: Will PSMA PET Replace Painful Prostate Biopsy? Yes

The 2026 ProsTIC annual meeting featured a PSMA imaging session and a presentation by Dr. Yao Zhu discussing that PSMA PET will replace painful prostate biopsies. The key message of Dr. Zhu’s ...